Market Place
Sourcing Support
All News #Library
Biotech
Volition Shows Lung Cancer Risk Data At ELCC Conference
26 Mar 2026 //
PR NEWSWIRE
Volition Announces Detection Of Over 95% Of Early-Stage Cancers
25 Mar 2026 //
PR NEWSWIRE
VolitionRx Boosts Commercial Momentum With Multi-Pillar Strategy
25 Feb 2026 //
PR NEWSWIRE
Volition Presents Nu.Q Nets Data For New Indication
27 Jan 2026 //
PR NEWSWIRE
Volition Enhances Liquid Biopsy With 180-Fold Enrichment
11 Dec 2025 //
PR NEWSWIRE
Volition Announces 2 Abstracts at North American Lung Cancer
08 Dec 2025 //
PR NEWSWIRE
Volitionrx Initiates First Sale Of Nu.Q Cancer Assays
25 Nov 2025 //
PR NEWSWIRE
Volitionrx Plans Public Offering Of Common Stock And Warrants
09 Oct 2025 //
PR NEWSWIRE
Volition Inks First Human Out Licensing Agreement
09 Sep 2025 //
PR NEWSWIRE
Volition Rx Reports Q2 2025 Financials and Business Update
14 Aug 2025 //
PR NEWSWIRE
Nu.Q® Discover Boosts Global Adoption, Epigenetic Innovation
16 Jul 2025 //
PR NEWSWIRE
Volition Study Shows Nu.Q® H3.1. Linked to Sepsis
12 Jun 2025 //
PR NEWSWIRE
Volition presents two posters at ESMO Lung Cancer Congress 2025
28 Mar 2025 //
PR NEWSWIRE
VolitionRx Prices $2.3M Direct Offering
26 Mar 2025 //
PR NEWSWIRE
Volition Signs First Project Using High-Throughput NETosis Model
06 Feb 2025 //
PR NEWSWIRE
Volition appoints Dr Andrew Retter as Chief Medical Officer
19 Mar 2024 //
PR NEWSWIRE
VolitionRx Announces Pricing of $16.5M Underwritten Public Offering of Stock
01 Jun 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.